Literature DB >> 28129132

Expanding Accessibility to CD19-CAR T Cells: Commercializing a "Boutique" Therapy.

Premal Lulla1, Carlos A Ramos2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28129132      PMCID： PMC5363183          DOI： 10.1016/j.ymthe.2016.12.002

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  6 in total

1.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

Authors:  James N Kochenderfer; Mark E Dudley; Sadik H Kassim; Robert P T Somerville; Robert O Carpenter; Maryalice Stetler-Stevenson; James C Yang; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; Mark Raffeld; Steven Feldman; Lily Lu; Yong F Li; Lien T Ngo; Andre Goy; Tatyana Feldman; David E Spaner; Michael L Wang; Clara C Chen; Sarah M Kranick; Avindra Nath; Debbie-Ann N Nathan; Kathleen E Morton; Mary Ann Toomey; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

2.  Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.

Authors:  Yang Xu; Ming Zhang; Carlos A Ramos; April Durett; Enli Liu; Olga Dakhova; Hao Liu; Chad J Creighton; Adrian P Gee; Helen E Heslop; Cliona M Rooney; Barbara Savoldo; Gianpietro Dotti
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

3.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

4.  Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

Authors:  B Coiffier; C Haioun; N Ketterer; A Engert; H Tilly; D Ma; P Johnson; A Lister; M Feuring-Buske; J A Radford; R Capdeville; V Diehl; F Reyes
Journal:  Blood       Date:  1998-09-15       Impact factor: 22.113

5.  CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Authors:  Renier J Brentjens; Marco L Davila; Isabelle Riviere; Jae Park; Xiuyan Wang; Lindsay G Cowell; Shirley Bartido; Jolanta Stefanski; Clare Taylor; Malgorzata Olszewska; Oriana Borquez-Ojeda; Jinrong Qu; Teresa Wasielewska; Qing He; Yvette Bernal; Ivelise V Rijo; Cyrus Hedvat; Rachel Kobos; Kevin Curran; Peter Steinherz; Joseph Jurcic; Todd Rosenblat; Peter Maslak; Mark Frattini; Michel Sadelain
Journal:  Sci Transl Med       Date:  2013-03-20       Impact factor: 17.956

6.  Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.

Authors:  Frederick L Locke; Sattva S Neelapu; Nancy L Bartlett; Tanya Siddiqi; Julio C Chavez; Chitra M Hosing; Armin Ghobadi; Lihua E Budde; Adrian Bot; John M Rossi; Yizhou Jiang; Allen X Xue; Meg Elias; Jeff Aycock; Jeff Wiezorek; William Y Go
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454
  6 in total
  2 in total

1.  CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape.

Authors:  David Pettitt; Zeeshaan Arshad; James Smith; Tijana Stanic; Georg Holländer; David Brindley
Journal:  Mol Ther       Date:  2017-11-02       Impact factor: 11.454

Review 2.  Management of the Critically Ill Adult Chimeric Antigen Receptor-T Cell Therapy Patient: A Critical Care Perspective.

Authors:  Cristina Gutierrez; Colleen McEvoy; Elena Mead; R Scott Stephens; Laveena Munshi; Michael E Detsky; Stephen M Pastores; Joseph L Nates
Journal:  Crit Care Med       Date:  2018-09       Impact factor: 9.296
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.